FDA Approves New Hepatitis C Treatment Mavyret for All Genotypes

FacebookTwitterLinkedInEmailPrint

The U.S. FDA approved Hepatitis C treatment Mavyret, for all genotypes, for patients without cirrhosis and those with compensated cirrhosis as well as patients with genotype 1 who have been previously treated with an HCV NS5A inhibitor or NS3/4A protease inhibitor but not both and for patients with severe kidney disease, including those on dialysis. …

HealthCare News Newspaper roll with white background
Continue Reading »